Health Technology Kyowa Kirin Co., Ltd. Business Summary
Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It handles the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. It also produces and sells medical and industrial raw materials such as amino acids, nucleic acid-related compounds, and healthcare products. The company was founded by Benzaburo Kato on July 1, 1949 and is headquartered in Tokyo, Japan.
Financial Highlights
Dec 2020
JPY USD Revenue 318,352M 2,981.70M Gross Profit 227,827M 2,133.84M Operating income 55,419M 519.05M Income before tax 52,263M 489.49M Net income 47,027M 440.45M EBITDA 75,885M 710.74M Diluted EPS 87.49 0.81 Dividends Per Share 44 0.41 Total Assets 801,290M 7,761.05M Total liabilities 102,893M 996.59M Total equity 698,396M 6,764.45M Operating cash flow 39,502M 369.97M Currency in JPY Currency in USD
Historical Data Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Revenue
347,956M
353,380M
271,510M
305,820M
318,352M
Gross Profit
204,610M
215,972M
188,834M
215,129M
227,827M
Operating income
51,468M
62,209M
50,403M
53,354M
55,419M
Income before tax
42,877M
55,849M
66,841M
44,492M
52,263M
Net income
30,450M
42,899M
49,230M
37,674M
47,027M
EBITDA
75,252M
84,241M
66,646M
72,151M
75,885M
Diluted EPS
55.59
78.30
99.29
43.12
87.49
Dividends Per Share
25
27
35
42
44
Total Assets
683,801M
708,295M
741,982M
784,453M
801,290M
Total liabilities
106,766M
92,268M
92,589M
106,203M
102,893M
Total equity
577,036M
616,028M
649,621M
678,250M
698,396M
Operating cash flow
66,881M
64,902M
56,181M
53,655M
39,502M
Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Revenue
3,202.27M
3,151.41M
2,458.37M
2,805.40M
2,981.70M
Gross Profit
1,883.04M
1,926.02M
1,709.78M
1,973.46M
2,133.84M
Operating income
473.66M
554.77M
456.37M
489.43M
519.05M
Income before tax
394.60M
498.05M
605.20M
408.14M
489.49M
Net income
280.23M
382.57M
445.75M
345.59M
440.45M
EBITDA
692.55M
751.25M
603.44M
661.87M
710.74M
Diluted EPS
0.51
0.69
0.89
0.39
0.81
Dividends Per Share
0.23
0.24
0.31
0.38
0.41
Total Assets
5,862.74M
6,287.57M
6,762.81M
7,218.33M
7,761.05M
Total liabilities
915.38M
819.06M
843.90M
977.25M
996.59M
Total equity
4,947.36M
5,468.51M
5,920.98M
6,241.08M
6,764.45M
Operating cash flow
615.51M
578.79M
508.68M
492.19M
369.97M
Valuation Measures
Dec 2020
PER 32.13 ROA 5.93% ROE 6.83% Operating margin 17.40% Profit margin 14.77%
Key executives
President, CEO & Representative Director:
Masashi Miyamoto
Executive Officer, Manager-Accounting & Finance:
Motohiko Kawaguchi
Executive Officer, GM-Research & Development:
Mitsuo Satoh
Representative Director & Executive Vice President:
Yutaka Osawa
Executive Officer & General Manager-Sales:
Hiroshi Sugitani Shareholders
Kirin Holdings Co., Ltd. (53.4%)
Nomura Asset Management Co., Ltd. (3.6%)
Daiwa Asset Management Co. Ltd. (1.7%)
Nikko Asset Management Co., Ltd. (1.6%)
Massachusetts Financial Services Co. (1.2%)
The Vanguard Group, Inc. (1.1%)
BlackRock Fund Advisors (0.8%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
Norges Bank Investment Management (0.7%)
JPMorgan Asset Management (UK) Ltd. (0.6%)
Contact Details Website: http://www.kyowa-kirin.co.jp Address:
Otemachi Financial City Grand Cube,
1-9-2 Otemachi,
Tokyo,
100-0004,
Japan
Phone:
+81.3.5205.7200
Related Companies
Kyowa Kirin Australia Pty Ltd.
Kyowa Kirin Pharma FZ LLC
Kyowa Kirin Malaysia Sdn. Bhd.
Kyowa Kirin Korea Co., Ltd.
Kyowa Kirin Pharma SRL
Kyowa Kirin Pharma sro
Kyowa Kirin Austria GmbH
Kyowa Kirin SARL
Kyowa Kirin AB
Kyowa Kirin Pharma BV
Kyowa Kirin Holdings BV
Kyowa Kirin Farmaceutica SL
Kyowa Kirin Ireland Ltd.
Kyowa Kirin Canada, Inc.
Kyowa Kirin Frontier Co., Ltd.
Kyowa Medical Promotion Co., Ltd.
Kyowa Kirin GmbH
Strakan International SARL
Kyowa Kirin Plus Co., Ltd.
Kyowa Hakko Bio Co. Ltd. (Beijing)
Kyowa Hakko Bio (Shanghai) Trading Co., Ltd.
Kyowa Hakko Bio (Shanghai) Trading Co. Ltd. /Beijing Branch/
Kyowa Hakko Bio Shanghai Trading Co. Ltd. /Guangzhou/
Kyowa Hakko Kirin (Hong Kong) Co. Ltd.
Kyowa Hakko Kirin (Taiwan) Co. Ltd.
Kyowa Hakko Kirin (Singapore) Pte Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
Kyowa Hakko Kirin (Thailand) Co. Ltd.
ProStrakan SRL
Kyowa Hakko Kirin America, Inc.
Competitors
Genexine, Inc.
Enzychem Lifesciences Corp.
FibroGen, Inc.
Innate Pharma SA Class A
Tetralogic Pharmaceuticals Corporation
Seagen, Inc.
arGEN-X SE
Heron Therapeutics Inc
RAPT Therapeutics, Inc.
Tonix Pharmaceuticals Holding Corp.
Copyright © 2021 FactSet Research Systems Inc. All rights reserved.
Last Updated on 1 Dec, 2021
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more